Building a broad pipeline in autoimmune
diseases & cancer

Our lead product candidate, ADI-001, is a first-in-class investigational allogeneic gamma delta CAR T cell therapy currently being developed in two indications. It’s being studied in an ongoing Phase 1 trial for the treatment of relapsed or refractory aggressive B-cell NHL and in a Phase 1 study in lupus nephritis (an autoimmune disease caused by systemic lupus erythematosus (SLE)).

In Autoimmune Diseases

ADI-001 is ideally suited for the treatment of autoimmune diseases given its robust B-cell depletion consistent with other autologous CAR T therapies tested in autoimmune diseases, its tissue tropism potential, and the safety data observed in our oncology Phase 1 study.

FDA cleared the IND application for ADI-001 in lupus nephritis in December, 2023. Adicet plans to initiate a Phase 1 study to evaluate the safety and efficacy of ADI-001 in lupus nephritis in Q2 2024.

In Cancer

ADI-001 targets malignant B-cells with an anti-CD20 CAR via the gamma delta innate and T cell endogenous cytotoxicity receptors. Gamma delta T cells engineered with an anti-CD20 CAR have demonstrated potent antitumor activity in preclinical models, leading to long-term control of tumor growth.

ADI-001 has shown encouraging early efficiacy and favorable safety in heavily pretreated aggressive NHL patients in initial Phase 1 clinical studies.

In April 2022, ADI-001 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of relapsed or refractory B-cell NHL.

• ADI-270, an armored CD70 CAR γδ T cell targeting CD70 via the CD27-ligand, has shown superiority to scFv (single-chain variable fragment) CARs¹
• Innate and adaptive targeting mechanisms associated with activity in solid tumors such as renal cell carcinoma (RCC) and other indications
• Armoring via dominant negative receptor; addresses TGFβ in Tumor Microenvironment² 
• Lead CAR demonstrated potency and improved serial killing, and resilience against suppressive factors and graft vs host rejection
• Homing and activity of gamma delta 1 T cells demonstrated in RCC

¹​ Sauer et al. Blood (2021)
² Junker et al. Cytokine (2000)

• Potent CAR construct active against heterogeneous PSMA
• Three mechanisms of action designed to address tumor heterogeneity
• Homing of gamma delta 1 T cells documented in mCRPC
• Inclusion of armoring to address suppressive TME
• No significant CRS and ICANS demonstrated with Adicet CAR gamma delta 1 T cells in clinical trials reported to-date

Liu et al. Cancer Res. (1997)